Home - Products - Angiogenesis - FLT - TG-89

TG-89

CAS No. 936091-56-4

TG-89( —— )

Catalog No. M33687 CAS No. 936091-56-4

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	34	In Stock
5MG	63	In Stock
10MG	98	In Stock
25MG	164	In Stock
50MG	231	In Stock
100MG	312	In Stock
200MG	429	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

TG-89
Note

Research use only, not for human use.
Brief Description

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
Description

JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

FLT
Recptor

FLT | JAK | c-RET
Research Area

——
Indication

——

Chemical Information

CAS Number

936091-56-4
Formula Weight

510.65
Molecular Formula

C26H34N6O3S
Purity

>98% (HPLC)
Solubility

——
SMILES

Cc1cnc(Nc2cccc(CN3CCOCC3)c2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Glenn Noronha, et al. Bi-aryl meta-pyrimidine inhibitors of kinases. Patent. US20110212077A1.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

FLT3-IN-2

FLT3-IN-2 is a FLT3 inhibitor with IC50 of ＜ 1 μM.
FLT3-IN-4

FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3;?IC50=7 nM) inhibitor ,for treating acute myelogenous leukemia.
Merestinib dihydroch...

Merestinib dihydrochloride (LY2801653 dihydrochloride) is an orally available kinase inhibitor with antitumor activity that inhibits MET, AXL, RON, and MKNK1/2, and inhibits the growth of NTRK fusion-carrying tumors.

Sign In Join Free